BIOCODEX

Biocodex is a family-owned multinational pharmaceutical company based in France, established in 1953. It has a strong focus on microbiota care and is recognized for marketing the world's first probiotic yeast strain, *Saccharomyces boulardii* CNCM I-745®. The company operates in over 100 countries, serving millions of patients through its subsidiaries and partnerships. Biocodex specializes in three key areas: microbiota care, women's health, and orphan diseases. Its flagship product, *Saccharomyces boulardii* CNCM I-745®, is widely used for gastrointestinal health. The company also develops treatments for rare diseases and offers products tailored to women's health needs. With a dedicated R&D center in France, Biocodex is committed to innovation and invests in startups focused on health solutions. The company employs over 1,700 people from diverse backgrounds and is governed by a Board of Directors and an Executive Committee. Biocodex reported a revenue of €567 million, supporting its operations across multiple facilities in France and Morocco.